Wision AI: The world's first independent external randomized controlled trial in the field of medical AI published

Shanghai, September 30, 2021/PRNewswire/ - In September 2021, the leader in the field of medical optical imaging-assisted diagnostics, Vision AI announced that its main research product EndoScreener (colonoscopy-assisted diagnostic software) is in the United States The clinical performance was excellent in multi-center clinical trials, and the results [1] were published in the top journal of Gastroenterology "Clinical Gastroenterology & Hepatology" [IF=11.

The study was led by Professor Tyler M.

This clinical trial is not only the first randomized controlled trial (RCT) of artificial intelligence (AI) assisted diagnostic equipment (CAD) in the medical field of the United States, but also the world's first independent external randomized controlled trial of medical artificial intelligence technology

Excellent clinical results under rigorous and demanding high-baseline parallel & cross-control design

As we all know, colonoscopy is the gold standard for colorectal cancer screening, and detecting more adenomas may reduce the incidence and mortality of colorectal cancer [2]

In this study, a classic tandem crossover trial design was used.

The test results showed that the intervention of AI software significantly increased the average number of adenomas detected per colonoscopy (0.

Not only that, after the use of AI software, the adenoma detection rate of 10 doctors was as high as 50.

Moreover, in the AI-assisted examination, the false positives of each colonoscopy are less than once.

It can be seen that EndoScreener has shown excellent auxiliary diagnostic performance in the real clinical environment

Crossover test design

The world's first independent external randomized controlled trial evidence of medical AI

The significance of this research beyond the clinical utility is also very significant.

The EndoScreener assisted diagnosis system was developed using data from a western hospital in China.

The verification of purely external randomized controlled trials can more rigorously test the effectiveness, generalization and robustness of the software, but it is undoubtedly a huge challenge

Example of EndoScreener identifying polyps

AI technology from Shanghai, China

According to the published paper, the colonoscopy-assisted diagnosis software EndoScreener was developed by Wision AI in Shanghai, China

Attendance speech map

[1] Jeremy R.

[2] Kaminski MF, regula J, Kraszewska e, et al.

[3] Wang P, Xiao X, Glissen Brown JR, et al.

[4] Wang P, Berzin TM, Glissen Brown JR, et al.
Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomized controlled study.
Gut.
2019;68(10):1813-9.
Epub 2019/03/01

[5] Wang P, Liu X, Berzin TM, et al.
Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomized study.
Lancet Gastroenterol Hepatol.
2020 ;5(4):343-51.
Epub 2020/01/26

[6] Liu P, Wang P, Glissen Brown JR, et al.
The single-monitor trial: an embedded CADe system increased adenoma detection during colonoscopy: a prospective randomized study.
Therapeutic Advances in Gastroenterology.
2020;13:1756284820979165.

[7] Wang P, Liu P, Glissen Brown JR, et al.
Lower Adenoma Miss Rate of Computer-Aided Detection-Assisted Colonoscopy vs Routine White-Light Colonoscopy in a Prospective Tandem Study.
Gastroenterology.
2020;159(4):1252 -1261.
e5.
doi:10.
1053/j.
gastro.
2020.
06.
023

Wision AI is an artificial intelligence (AI) medical imaging software company.
It aims to use a small number of developed samples to realize the clinical value of AI under the framework of functional analysis theory, and to provide digital medical innovation at the level of rewriting clinical guidelines for the field of medical optical imaging
.

Source: Wision AI Weizhi Medical